Tidal Investments LLC Sells 4,614 Shares of Solventum Co. (NYSE:SOLV)

Tidal Investments LLC lowered its position in shares of Solventum Co. (NYSE:SOLV) by 15.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,823 shares of the company’s stock after selling 4,614 shares during the quarter. Tidal Investments LLC’s holdings in Solventum were worth $1,800,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB boosted its position in Solventum by 196.7% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 17,062 shares of the company’s stock worth $1,190,000 after acquiring an additional 11,312 shares during the last quarter. Sanctuary Advisors LLC boosted its position in Solventum by 95.6% during the 3rd quarter. Sanctuary Advisors LLC now owns 19,074 shares of the company’s stock worth $1,351,000 after acquiring an additional 9,323 shares during the last quarter. Virtu Financial LLC acquired a new position in Solventum during the 3rd quarter worth approximately $568,000. Toronto Dominion Bank boosted its position in Solventum by 1.6% during the 3rd quarter. Toronto Dominion Bank now owns 71,096 shares of the company’s stock worth $4,957,000 after acquiring an additional 1,111 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Solventum by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock worth $232,608,000 after acquiring an additional 128,317 shares during the last quarter.

Solventum Trading Down 1.0 %

SOLV opened at $68.60 on Wednesday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The stock’s fifty day simple moving average is $71.00 and its 200 day simple moving average is $63.38. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SOLV. Stifel Nicolaus began coverage on Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price target for the company. BTIG Research started coverage on Solventum in a report on Thursday, September 5th. They issued a “neutral” rating for the company. Piper Sandler increased their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Wolfe Research started coverage on Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating for the company. Finally, Morgan Stanley increased their price objective on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.